Standard BioTools will host a conference call and webcast on May 6 th, 2025, at 4:30 p.m. ET to discuss the first quarter ...

Gross margins in the first quarter of 2025 were ... of the Company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results ...

The Board will review the Share Repurchase Plan periodically and may authorize adjustment of its terms and size or suspend or ...

Q1 revenues: $16.8 million, exceeding the top end of our guidance. Q1 gross margin: 62.9% GAAP; 66.7% non-GAAP. Cash, cash equivalents and short-term deposits: ...

Management reaffirms mid-teens percentage sales growth for the full year 2025, incorporating contributions from Nissens. Adjusted EBITDA margin is projected to range between 10% and 11% of net sales.

A reconciliation of the Company’s forward-looking Adjusted Gross Profit Margin, Adjusted EBITDA and Adjusted Diluted EPS guidance to the most directly comparable GAAP financial measures is not ...

Achieves Quarterly Revenue of $97 Million, an Increase of 13% from Prior Year QuarterDelivers Net Income of $3 Million and Expands Gross Margin 170 Basis Points to 39% from Prior Year QuarterReaffirms ...

AMD announced support of the latest UALink 1.0 specification, an open, industry-standard ... plus or minus $300 million. Non-GAAP gross margin is estimated to be 43% inclusive of approximately ...

Second quarter 2025 net revenues are expected to be $14.0 to $15.0 million. Non-GAAP gross margin for the second quarter is expected to be 38.5% plus or minus 50 basis points, and non-GAAP ...

The following provides additional explanations for non-GAAP financial measures used by ... Adjusted Operating Income and Adjusted Operating Margin. The Company also excludes foreign exchange ...